[go: up one dir, main page]

PE20021138A1 - Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata - Google Patents

Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata

Info

Publication number
PE20021138A1
PE20021138A1 PE2002000438A PE2002000438A PE20021138A1 PE 20021138 A1 PE20021138 A1 PE 20021138A1 PE 2002000438 A PE2002000438 A PE 2002000438A PE 2002000438 A PE2002000438 A PE 2002000438A PE 20021138 A1 PE20021138 A1 PE 20021138A1
Authority
PE
Peru
Prior art keywords
prostate
diseases
treatment
antiprogestines
compositions
Prior art date
Application number
PE2002000438A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Jens Hoffmann
Gerhard Siemeister
Martin Schneider
Rosemarie Lichtner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20021138A1 publication Critical patent/PE20021138A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE LA ANTIPROGESTINA 11ß-(4-ACETILFENIL)-17ß-HIDROXI-17O-(1,1,2,2,2-PENTAFLUOROETIL)-ESTRA-4,9-DIEN-3-ONA, UN DERIVADO O ANALOGO DE LA MISMA UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DE LA PROSTATA COMO CANCER EN UNA CANTIDAD DE 50 mg A 100mg. LA ANTIPROGESTINA SE PUEDE COMBINAR CON UN DERIVADO U OTRO AGENTE TERAPEUTICO SELECCIONADO DE ANTIOANDROGENOS, ESTROGENOS, ANTIESTROGENOS, INHIBIDORES DE LA 5a-REDUCTASA, DROGAS CITOSTATICAS, ENTRE OTROS
PE2002000438A 2001-05-25 2002-05-24 Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata PE20021138A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01250185 2001-05-25

Publications (1)

Publication Number Publication Date
PE20021138A1 true PE20021138A1 (es) 2003-01-11

Family

ID=8181589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000438A PE20021138A1 (es) 2001-05-25 2002-05-24 Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata

Country Status (6)

Country Link
EP (1) EP1392399A1 (es)
JP (2) JP2004531561A (es)
AR (1) AR034046A1 (es)
PE (1) PE20021138A1 (es)
UY (1) UY27301A1 (es)
WO (1) WO2002094379A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE4039561A1 (de) * 1990-12-07 1992-07-09 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE4318371A1 (de) * 1993-05-28 1994-12-01 Schering Ag Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
EE05259B1 (et) * 2000-10-18 2010-02-15 Schering Aktiengesellschaft Antiprogestiinide kasutamine hormoons?ltuvate haiguste proflaktikaks ja raviks
ATE334683T1 (de) * 2000-10-18 2006-08-15 Schering Ag Verwendung von 11beta-(4-acetylphenyl)-17beta-

Also Published As

Publication number Publication date
JP2010077157A (ja) 2010-04-08
WO2002094379A1 (en) 2002-11-28
EP1392399A1 (en) 2004-03-03
AR034046A1 (es) 2004-01-21
UY27301A1 (es) 2003-02-28
JP2004531561A (ja) 2004-10-14

Similar Documents

Publication Publication Date Title
BRPI0415971A (pt) método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
MA26843A1 (fr) NOUVELLES COMPOSITIONS ESTRO-PROGESTATIVES TOPIQUES à EFFET SYSTÉMIQUE
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
EA200500149A1 (ru) Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов
ATE538801T1 (de) Therapeutische zusammensetzungen mit mindestens einem pyrrolobenzodiazepin-derivat und fludarabin
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
CY1113967T1 (el) Μη-υδατικη φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση περιλαμβανουσα βιταμινη d, κορτικοστεροειδες και ενα συστατικο διαλυτη
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
AR004089A1 (es) Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante.
ATE382356T1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
DK1328276T3 (da) Anvendelse af antiprogestiner til profylakse og behandling af hormonafhængige sygdomme
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
GT200000194A (es) Quimioterapia de combinacion.
BR0315931A (pt) Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
PE20021138A1 (es) Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata

Legal Events

Date Code Title Description
FA Abandonment or withdrawal